Becker's Healthcare November 26, 2024
Patient advocacy groups are expressing frustration over the federal government’s lack of progress in identifying long COVID treatments, NPR reported Nov. 25.
Although the government has allocated $1.15 billion for long COVID research, no new treatments have emerged for the estimated 17 million adults living with the condition, according to CDC figures.
“It’s unconscionable that more than four years since this began, we still don’t have one FDA- approved drug,” Meighan Stone, executive director of Long COVID Campaign, a patient advocacy group, told NPR.
The National Institutes of Health’s long COVID research initiative has largely focused on observational and pathobiology studies to understand how the condition’s effects, rather than clinical trials for potential treatments. Ziyad Al-Aly, MD,...
Today's Sponsors
Today's Sponsor